Trials / Recruiting
RecruitingNCT06271512
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Genetix Biotherapeutics Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | This is non-interventional study. |
Timeline
- Start date
- 2024-01-23
- Primary completion
- 2043-12-01
- Completion
- 2043-12-01
- First posted
- 2024-02-21
- Last updated
- 2025-02-11
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06271512. Inclusion in this directory is not an endorsement.